FMPV-1 is under clinical development by Hubro Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FMPV-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FMPV-1 overview

FMPV-1 is under development for the treatment of colorectal cancer. It is administered through intradermal route. The therapeutic candidate is a peptide-based cancer vaccine targeting transforming growth factor beta receptor 2. It is developed based on neo-peptide technology platform.

Hubro Therapeutics overview

Hubro Therapeutics (Hubro) is engaged in healthcare service that develops neoantigen targeted cancer vaccines for cancer treatment. The company is headquartered in Ullern, Oslo, Norway

For a complete picture of FMPV-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.